Physician profile
Steven M Moore
NPI 1023114097
$1,506.16
in general payments reported to CMS, 2019-2025
15 companies · $473 in 2025
The $473 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.68 · 2020: $95.24 · 2021: $117 · 2022: $211 · 2023: $299 · 2024: $235 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $404.99 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $251.76 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $167.93 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $167.43 | 2020-2023 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $149.42 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $87.78 | 2024 | |
| Corium, LLC | $52.53 | 2022 | |
| Verrica Pharmaceuticals INC. | $47.89 | 2024 | Ycanth |
| Sanofi Pasteur INC. | $38.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $32.32 | 2024 | Flumist Quadrivalent |
| Sobi, INC | $26.94 | 2022 | |
| Biomarin Pharmaceutical INC. | $25.17 | 2025 | Voxzogo 1.2mg |
| Biogen, INC. | $19.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.09 | 2020 | |
| Tris Pharma INC | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.